Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LT-012
- Development stage
- Preclinical
- Lead developer
- lncTAC Bio
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
LT-012 is a preclinical-stage pan-tumor delivery platform developed by lncTAC Bio (Chengdu Lingtaike Biotechnology). It is designed for the delivery of small nucleic acid therapeutics using a long non-coding RNA (lncRNA) vector. The platform leverages lncTAC Bio's proprietary lncRNA-based technology to overcome traditional delivery and stability challenges of nucleic acid drugs, enabling targeted delivery to tumor tissues.
Beyond the preview
Go deeper on LT-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LT-012.